Search Results

Suggested Topics within your search.
Refine Results
  1. 1
    Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity

    Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity by Gleison Vieira Duarte, Vanessa Lys Simas Yamakawa Boeira, Thiago Macêdo Lopes Correia, Larissa Porto-Silva, Thiago M. Cardoso, Michael Nascimento Macedo, Michelli F. Oliveira, Edgar M. Carvalho

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial

    Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial by Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients

    IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients by Priscilla Stela Santana de Oliveira, Pablo Ramon Gualberto Cardoso, Émerson Silva Lima, Michelly Cristiny Pereira, Ângela Luzia Branco Pinto Duarte, Ivan da Rocha Pitta, Moacyr Jesus Barreto de Melo Rêgo, Maíra Galdino da Rocha Pitta

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis

    Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis by Renata Nahas Cardili, Taïna Alves, J.C.O.C. Freitas, Christiane Pienna Soares, Celso Teixeira Mendes‐Junior, Edson Garcia Soares, Eduardo Antônio Donadi, Cacilda da Silva Souza

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris

    Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris by Karen S. Anderson, S. Petersson, Jennifer S. Wong, Emman Shubbar, Naa Lokko, Maria Carlström, Charlotta Enerbäck

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    <i>CCL20</i>and<i>IL22</i>Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis

    <i>CCL20</i>and<i>IL22</i>Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis by Ari M. Goldminz, Mayte Suárez‐Fariñas, Andrew C. Wang, Nicole Dumont, James G. Krueger, Alice B. Gottlieb

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

    A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis by Alice B. Gottlieb, Richard Langley, Bruce Strober, Kim Papp, Paul Klekotka, Kent Creamer, Elizabeth H. Thompson, M. Hooper, Greg Kricorian

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Tongue lesions in psoriasis: a controlled study

    Tongue lesions in psoriasis: a controlled study by Maryam Daneshpazhooh, H Moslehi, Maryam Akhyani, Marjan Etesami

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial

    Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinde... by Paolo Gisondi, Micol Del Giglio, Vincenzo Di Francesco, Mauro Zamboni, Giampiero Girolomoni

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Serum Vascular Endothelial Growth Factor, Transforming Growth Factor β1, and Nitric Oxide Levels in Patients With Psoriasis Vulgaris: Their Correlation to Disease Severity

    Serum Vascular Endothelial Growth Factor, Transforming Growth Factor β1, and Nitric Oxide Levels in Patients With Psoriasis Vulgaris: Their Correlation to Disease Severity by Abdel‐Raheim M.A. Meki, Hani A. Al‐Shobaili

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

    Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study by Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Alain Taı̈eb, Sandra Philipp, Philippe Szapary, B. Randazzo

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Teledermatological Monitoring of Psoriasis Patients on Biologic Therapy

    Teledermatological Monitoring of Psoriasis Patients on Biologic Therapy by Sílvia Helena Koller, R Hofmann‐Wellenhof, Dieter Hayn, Wolfgang Weger, Peter Kästner, G. Schreier, W Salmhofer

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients

    Decreased brain-derived neurotrophic factor plasma levels in psoriasis patients by André R. Brunoni, Paulo A. Lotufo, Cid Yazigi Sabbag, Alessandra C. Goulart, Itamar S Santos, Isabela M. Benseñor

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin

    NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin by Maira Mitsue Mukai, Isabela Fleischfresser Poffo, Betina Werner, Fabiane Mulinari Brenner, José Hermênio Cavalcante Lima Filho

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis

    Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis by Alexander Nast, Anja Jacobs, Stefanie Rosumeck, Ricardo Niklas Werner

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study

    Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study by Robert Bissonnette, Yves Poulin, Lyn Guenther, Charles Lynde, Chantal Bolduc, Simon Nigen

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

    Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results fro... by Bruce Strober, Jeffrey M. Sobell, Kristina Callis Duffin, Yanjun Bao, A. Guérin, Hongbo Yang, Orin M. Goldblum, Martin M. Okun, P.M. Mulani

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial by Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

    Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest by Kristian Reich, Ulrich Mrowietz, Marc Alexander Radtke, Diamant Thaçi, Stephan Jeff Rustenbach, C. Spehr, Matthias Augustin

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis.

    Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. by Marion Laurent, G S Panayi, P Shepherd

    Published 1981
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: